Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | ERN1 | O75460 | 6/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | STK4 | Q13043 | 1/20 | 0.32 |
| ▸ | STK3 | Q13188 | 1/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2456169 | 0.75 | CCR1 (0.37) | — | |
| SCHEMBL474098 | 0.75 | BTK (0.41) | — | |
| SCHEMBL7471772 | 0.74 | TMIGD3 (0.33) | TMIGD3ADORA1PDGFRB | |
| SCHEMBL8327153 | 0.74 | GRIA1 (0.37) | ERN1CDK8CCNT1CDK9 | |
| SCHEMBL8963381 | 0.72 | NISCH (0.42) | — | |
| SCHEMBL15330860 | 0.72 | IDO1 (0.38) | — | |
| SCHEMBL15332789 | 0.72 | KDM4E (0.38) | — | |
| SCHEMBL15331942 | 0.72 | ALDH1A1 (0.41) | — | |
| SCHEMBL15331294 | 0.72 | MAP2K1 (0.33) | — | |
| SCHEMBL15330777 | 0.72 | TNKS2 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-8927738-B2 | 2-arylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2015-01-06 | — | — | US | disclosed |
| US-8927738-B2 | 2-arylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2015-01-06 | — | — | US | disclosed |
| EP-2513105-B1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | LUNDBECK & CO AS H (DK) | 2014-05-14 | — | — | EP | disclosed |
| EP-2513105-B1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | LUNDBECK & CO AS H (DK) | 2014-05-14 | — | — | EP | disclosed |
| US-20130289038-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2013-10-31 | — | — | US | disclosed |
| US-20130289038-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2013-10-31 | — | — | US | disclosed |
| US-8501797-B2 | (2-aryl-1H-imidazol-4-yl)-linked heterocycle derivatives | H. LUNDBECK A/S (DK) | 2013-08-06 | — | — | US | disclosed |
| US-8501797-B2 | (2-aryl-1H-imidazol-4-yl)-linked heterocycle derivatives | H. LUNDBECK A/S (DK) | 2013-08-06 | — | — | US | disclosed |
| US-8501797-B2 | (2-aryl-1H-imidazol-4-yl)-linked heterocycle derivatives | H. LUNDBECK A/S (DK) | 2013-08-06 | — | — | US | disclosed |
| US-20120302548-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2012-11-29 | — | — | US | disclosed |
| US-20120302548-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2012-11-29 | — | — | US | disclosed |
| US-20120302548-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2012-11-29 | — | — | US | disclosed |
| WO-2011072696-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289038-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE12, PDE3B, PDE5A | TMIGD3 3330/4885ADORA1 326/4885ERN1 2528/4885 |
| US-20120302548-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE12, PDE3B, PDE5A | TMIGD3 3330/4885ADORA1 326/4885ERN1 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.